A once-daily pill that pushed back the onset of debilitating vaso-occlusive crises by roughly four months could soon face its most consequential test: regulatory scrutiny on two continents.
Novo Nordisk (NYSE: NVO) has filed applications with both the US Food and Drug Administration and the European Medicines Agency seeking marketing approval for etavopivat, an oral therapy targeting sickle cell disease in adolescents and adults aged 12 and older.
Decisions from both agencies are anticipated during 2027, marking the next critical checkpoint for a drug that has taken on growing importance within the Danish pharmaceutical giant’s pipeline.
The clinical case for etavopivat rests on findings from the Phase 3 HIBISCUS study programme, whose topline results were disclosed in April 2026.
Against placebo, etavopivat cut the rate of vaso-occlusive crises by 27%, while also pushing back the timing of a patient’s first such crisis by approximately four months.
Vaso-occlusive crises arise when misshapen red blood cells block circulation, triggering painful episodes that can cause serious organ complications and significantly reduce quality of life.
Importantly, participants in HIBISCUS were permitted to maintain their existing standard-of-care regimens alongside the investigational drug, meaning the trial assessed etavopivat as an add-on rather than a replacement therapy.
Complete efficacy and safety data from the programme have yet to be released publicly, with Novo Nordisk planning to present the full results at a scientific conference and submit them to a peer-reviewed journal.
The drug works by selectively activating the red blood cell isozyme of pyruvate kinase, an enzyme central to cellular energy metabolism, a mechanism designed to improve the function of abnormal red blood cells produced in sickle cell disease.
Martin Holst Lange, Executive Vice President and Chief Scientific Officer at Novo Nordisk, framed the submission against a backdrop of persistent therapeutic scarcity, stating bluntly that “treatment options remain limited” for patients living with the condition.
Etavopivat has accumulated several regulatory advantages ahead of the review process, having received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA, while the European Commission separately granted it Orphan Drug status.
Those designations acknowledge the unmet medical need and the drug’s development characteristics, though they carry no guarantee of ultimate approval.
The dual filing represents a deliberate expansion of Novo Nordisk’s regulatory ambitions beyond its core franchises in diabetes and obesity, into the rare disease space where competition is less entrenched but patient populations are smaller.
Should regulators in Washington and Amsterdam reach positive conclusions next year, etavopivat would become an option for a population that has long faced a narrow menu of approved medicines.
